From October 28 to 30, the CPHI Worldwide 2025 was held at Messe Frankfurt in Germany. Henlius showcased its robust biologic pipeline and advanced R&D platform at booth #3.1A92. Henlius drew a large crowd at the booth and concluded the conference with over 70 meetings.
Ping Cao, Senior Vice President and Chief Business Development Officer at Henlius, stated, “As one of the most influential events in the global pharmaceutical industry, CPHI Worldwide convenes leading enterprises and experts from across the sector, serving as a key platform for in-depth engagement in cutting-edge technological discourse and strategic expansion of resources. Leveraging this opportunity, Henlius has further strengthened its global collaboration network and identified several potential partners. The company remains committed to advancing biopharmaceutical innovation through international cooperation and to delivering high-quality, affordable therapeutics to patients worldwide.”
At the conference, Henlius provided a comprehensive overview of its robust R&D pipeline, including HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, HANLIKANG (rituximab), the first China-developed biosimilar, and denosumab Bildyos® and Bilprevda®. In addition, core underdevelopment innovative products such as HLX43 (PD-L1 ADC), HLX22 (novel enpitope anti-HER2 mAb), and HLX07 (anti-EGFR mAb), have also attracted widespread attention. In addition, Henlius’ advanced platform, exemplified by Henozye®, proprietary next-generation recombinant human hyaluronidase platform, attracted significant attention at the exhibition and emerged collaboration discussions. Leveraging its exceptional enzyme stability and broad compatibility, the platform is poised to deliver efficient solutions for the development of high-concentration subcutaneous formulations and co-formulations across diverse therapeutic molecules, thereby enhancing product lifecycle value and improving patient convenience in drug administration. Throughout the event, Henlius team engaged in multiple rounds of productive discussions with representatives from numerous global biopharmaceutical companies, establishing a strong foundation for future partnerships.
Henlius is accelerating the global expansion of its products by partnering with experienced commercialization companies. Recently, the company has collaborated with Dr. Reddy’s to advance the clinical development of the anti-CD38 antibody HLX15, granted Lotus exclusive license for the commercialization and co-exclusive for the development of HANSIZHUANG, and reached an agreement with Sandoz to promote the commercialization of the ipilimumab biosimilar HLX13 in key markets including the US, Europe, and Japan. Henlius is also working closely with Accord, Eurofarma, Organon, and other international partners to speed up the registration and launch of multiple products worldwide, driving the global reach of China’s biopharmaceutical innovations.
Looking ahead, Henlius will continue to advance innovation and strengthen collaboration with global partners to accelerate the global delivery of high-quality, affordable treatment options for patients worldwide.